EP1538980B1 - Vorrichtung für die körperästhetik - Google Patents

Vorrichtung für die körperästhetik Download PDF

Info

Publication number
EP1538980B1
EP1538980B1 EP02743588.2A EP02743588A EP1538980B1 EP 1538980 B1 EP1538980 B1 EP 1538980B1 EP 02743588 A EP02743588 A EP 02743588A EP 1538980 B1 EP1538980 B1 EP 1538980B1
Authority
EP
European Patent Office
Prior art keywords
cellulite
ultrasonic
target volume
transducer
ultrasonic energy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP02743588.2A
Other languages
English (en)
French (fr)
Other versions
EP1538980A4 (de
EP1538980A1 (de
Inventor
Yoram Eshel
Leonid Kushculey
Ariel Sverdlik
Ilia Vitsnudel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ultrashape Ltd
Original Assignee
Ultrashape Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultrashape Ltd filed Critical Ultrashape Ltd
Publication of EP1538980A1 publication Critical patent/EP1538980A1/de
Publication of EP1538980A4 publication Critical patent/EP1538980A4/de
Application granted granted Critical
Publication of EP1538980B1 publication Critical patent/EP1538980B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B34/00—Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
    • A61B34/20—Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N7/02—Localised ultrasound hyperthermia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B34/00—Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
    • A61B34/20—Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
    • A61B2034/2046—Tracking techniques
    • A61B2034/2055—Optical tracking systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B34/00—Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
    • A61B34/20—Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
    • A61B2034/2046—Tracking techniques
    • A61B2034/2065—Tracking using image or pattern recognition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B34/00—Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
    • A61B34/20—Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
    • A61B2034/2072—Reference field transducer attached to an instrument or patient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/06—Measuring instruments not otherwise provided for
    • A61B2090/064—Measuring instruments not otherwise provided for for measuring force, pressure or mechanical tension
    • A61B2090/065—Measuring instruments not otherwise provided for for measuring force, pressure or mechanical tension for measuring contact or contact pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/36—Image-producing devices or illumination devices not otherwise provided for
    • A61B90/37—Surgical systems with images on a monitor during operation
    • A61B2090/378—Surgical systems with images on a monitor during operation using ultrasound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B34/00—Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
    • A61B34/25—User interfaces for surgical systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/36—Image-producing devices or illumination devices not otherwise provided for
    • A61B90/361—Image-producing devices, e.g. surgical cameras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/08—Lipoids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N2007/0004—Applications of ultrasound therapy
    • A61N2007/0008—Destruction of fat cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N2007/0078—Ultrasound therapy with multiple treatment transducers

Definitions

  • the present invention relates to body aesthetics generally and also to cellulite treatment and to devices and methodologies finding application therein.
  • the present invention seeks to provide improved apparatus and methodology for ultrasonic cellulite treatment.
  • the apparatus may be used for performing one or more of the following methods:
  • the methods may include ultrasonic imaging of the region at least partially concurrently with directing the focused ultrasonic energy at the target volume.
  • directing includes positioning at least one ultrasonic transducer relative to the body in order to direct the focused ultrasonic energy at the target volume.
  • the directing may also include varying the focus of at least one ultrasonic transducer in order to direct the focused ultrasonic energy at the target volume. Varying the focus may change the volume of the target volume, and/or the distance of the target volume from the at least one ultrasonic transducer.
  • the directing may also include positioning at least one ultrasonic transducer relative to the body in order to direct the focused ultrasonic energy at the target volume.
  • the methods may preferably also include sensing ultrasonic energy coupling to an external surface of the body adjacent the target volume.
  • the methods may preferably additionally include sensing of cavitation at the target volume.
  • directing takes place from an ultrasonic transducer located outside of the body.
  • the ultrasonic energy target volume is distal to the dermis and proximal to the fascia.
  • the ultrasonic energy has a frequency in a range of 50 KHz-1000 KHz, more preferably in a range of 100 KHz-500 KHz, and most preferably in a range of 150 KHz-300 KHz.
  • the modulating provides a duty cycle between 1: 5 and 1: 30 and most preferably between 1: 10 and 1: 20.
  • the modulating provides between 2 and 1000 sequential cycles at an amplitude above a cavitation threshold, more preferably between 25 and 500 sequential cycles at an amplitude above a cavitation threshold and most preferably between 100 and 300 sequential cycles at an amplitude above a cavitation threshold.
  • the modulating includes modulating the amplitude of the ultrasonic energy over time.
  • directing includes directing focused ultrasonic energy at a multiplicity of target volumes in a time sequence.
  • directing includes directing focused ultrasonic energy at plural ones of the multiplicity of target volumes at times, which at least partially overlap.
  • At least some of the multiplicity of target volumes at least partially overlap in space.
  • the apparatus may be used in a method including defining the region by marking at least one surface of the body.
  • the method may also include defining the region by selecting at least one depth in the body and/or by detecting cellulite in the body and/or by detecting non-lysed cellulite.
  • directing also includes defining the target volumes as unit volumes of non-lysed cellulite within the region.
  • modulating the ultrasonic energy so as to selectively lyse the cellulite in the multiplicity of target volumes proceeds sequentially in time wherein selective lysis of cellulite in each target volume takes place only following detection of non-lysed cellulite therein.
  • the methods may also include computerized tracking of the multiplicity of target volumes notwithstanding movement of the body.
  • the computerized tracking includes sensing changes in the position of markings on the body and employing sensed changes for tracking the positions of the target volumes in the body.
  • the modulation provides decreasing amplitude over time, which exceeds a cavitation threshold.
  • the destruction of the cells can be done, instead of by direct lysis of the cells membrane, by induction of apoptosis of the cells by ultrasonic energy from a source outside the body.
  • the apparatus for ultrasonic therapy comprises an ultrasonic energy director assembly comprising a plurality of Langevin ultrasonic transducers coupled together to provide focused ultrasonic energy on a target volume.
  • the plurality of Langevin ultrasonic transducers are embedded in a vibration damping material to avoid mechanical cross talk therebetween.
  • the apparatus for ultrasonic therapy includes a cooling system.
  • Cellulite is the appearance of an unattractive dimpled skin or "dimpled fat" on the outer thighs, buttocks and other body areas where large areas of fat are found in close proximity to the skin.
  • Cellulite is not a medical term but commonly refers to a "disease” that affects only women. Most women over the age of 18 have some degree of cellulite.
  • the gender specificity is an expression of the difference in the inner structural connection between the skin and subcutaneous tissues. Vertical fibrous tissue strands connect the skin to deeper tissue layers and create separate compartments that contain fat cells. When fat cells increase in size, these compartments bulge and produce a waffled appearance of the skin since the vertical connective septa are inelastic compared to the fat tissue.
  • the fat in the cellulite is the same like the fat tissue elsewhere. A person does not have to be overweight to develop this dimpled skin called cellulite. Cellulite is not always reduced by weight loss. Destruction of the fat content of cellulite is known to improve the skin appearance. The destruction can be achieved in accordance with the present invention by breaking cell membranes through the application of cavitational mechanical forces on the cells membranes or by induction of apoptosis, e.g. programmed cell death.
  • Fig. 1 is a simplified pictorial illustration of the general structure and operation of ultrasonic cellulite treatment apparatus constructed and operative in accordance with a preferred embodiment of the present invention.
  • an ultrasonic energy generator and director such as an ultrasonic transducer subsystem 10, disposed outside a body, generates ultrasonic energy which, by suitable placement of the transducer subsystem 10 relative to the body, is directed to a target volume 12 inside the body and is operative to selectively generally lyse cellulite and generally not lyse non-cellulite tissue in the target volume.
  • a preferred embodiment of ultrasonic energy generator and director useful in the present invention comprises an ultrasonic therapeutic transducer assembly 13 including a curved phased array 14 of transducers 15, typically defining a portion of a sphere or of a cylinder.
  • the transducers 15 may be of any suitable configuration, shape and distribution and are of a Langevin type.
  • a preferred Langevin type transducer is shown and includes a pair of piezoelectric elements 17 separated by positive contact electrode 18.
  • a metal bolt 19 cooperates with a metal disk 20 and a nut 21.
  • Negative contact electrodes 23 are located on both sides of the pair of piezoelectric elements 17 and held together tightly against the pair of piezoelectric elements 17 and the disk 20 by the bolt 19 and the nut 21. Pair of piezoelectric elements 17 can be multiplied to any even number of elements.
  • transducers 15 are embedded in a vibration damping material 24 to avoid mechanical cross talk between transducers 15.
  • An inner cooling system 25 may be associated with the transducers 15.
  • Contact surface 27 may be planar, but need not be.
  • Suitably modulated AC electrical power is supplied by conductors 28 to negative contact electrodes 23 to cause the transducers 15 to provide a desired focused acoustic energy output.
  • a cellulite imaging ultrasonic transducer subassembly 29 is incorporated within transducer assembly 13 and typically comprises a piezoelectric transducer 30 having conductive surfaces 31 associated with opposite surfaces thereof.
  • Suitably modulated AC electrical power is supplied by conductors 32 to conductive surfaces 31 in order to cause the piezoelectric transducer 30 to provide an acoustic energy output.
  • Conductors 32, coupled to conductive surfaces 31, also provide an imaging output from imaging ultrasonic transducer subassembly 29.
  • ultrasonic transducers may be employed for imaging or alternatively high frequency A-mode transducers may be used for this purpose.
  • cellulite imaging ultrasonic transducer subassembly 29 may be eliminated.
  • ultrasonic transducer assemblies 13 may be employed.
  • such transducer assemblies may include multiple Langevin type elements, multi-layered Langevin type elements and Langevin type elements of various shapes and sizes arranged in a phase array.
  • the ultrasonic energy generator and director are combined in transducer assembly 13.
  • the functions of generating ultrasonic energy and focusing such energy may be provided by distinct devices.
  • a skin temperature sensor 34 such as an infrared sensor, may be mounted in proximity to the contact surface 27as shown in Fig. 1
  • a transducer temperature sensor 36 such as a thermocouple, may also be mounted alongside imaging ultrasonic transducer subassembly 29.
  • Ultrasonic transducer subsystem 10 preferably receives suitably modulated electrical power from a power source and modulator assembly 40, forming part of a control subsystem 42.
  • Control subsystem 42 also typically includes a cellulite treatment control computer 44, having associated therewith a camera 46, such as a video camera, and a display 48.
  • a preferred embodiment of power source and modulator assembly 40 is illustrated in Fig. 2 and described hereinbelow.
  • Ultrasonic transducer subsystem 10 is preferably positioned automatically or semi-automatically as by an X- Y-Z positioning assembly 49. Alternatively, ultrasonic transducer subsystem 10 may be positioned at desired positions by an operator.
  • camera 46 is operative for imaging a portion of the body on which cellulite treatment is to be performed.
  • a picture of the portion of the patient's body viewed by the camera is preferably displayed in real time on display 48.
  • An operator may designate the outline of a region containing cellulite.
  • designation of this region is effected by an operator marking the skin of a patient with an outline 50, which outline is imaged by camera 46 and displayed on display 48 and is also employed by the cellulite treatment control computer 44 for controlling the application of ultrasonic energy to locations within the region.
  • a computer calculated representation of the outline may also be displayed on display 48, as designated by reference numeral 52.
  • the operator may make a virtual marking on the skin, such as by using a digitizer (not shown), which also may provide computer calculated outline representation 52 on display 48.
  • the functionality of the system of the present invention preferably also employs a plurality of markers 54 which are typically located outside the region containing cellulite, but may be located inside the region designated by outline 50.
  • Markers 54 are visually sensible markers, which are clearly seen by camera 46, captured by camera 46 and displayed on display 48.
  • Markers 54 may be natural anatomic markers, such as distinct portions of the body or alternatively artificial markers such as colored stickers. These markers are preferably employed to assist the system in dealing with deformation of the region nominally defined by outline 50 due to movement and reorientation of the body.
  • the transducer subsystem 10 also bears a visible marker 56 which is also captured by camera 46 and displayed on display 48.
  • Fig. 1 illustrates the transducer subsystem 10 being positioned on the body over a location within the region containing cellulite.
  • Blocks designated by reference numerals 62 and 64 show typical portions of a region containing cellulite, respectively before and after cellulite treatment in accordance with a preferred embodiment of the invention. It is seen from a comparison of blocks 62 and 64 that, in accordance with a preferred embodiment of the present invention, within the region containing cellulite, the cellulite, designated by reference numeral 66, is lysed, while non-cellulite tissue, such as connective tissue, designated by reference numeral 68, dermis designed by reference 69, fascia designated by reference 70 and deep fat designated by reference 67 are not lysed.
  • non-cellulite tissue such as connective tissue, designated by reference numeral 68, dermis designed by reference 69, fascia designated by reference 70 and deep fat designated by reference 67 are not lysed.
  • Fig. 2 is a simplified block diagram illustration of a preferred power source and modulator assembly 40 ( Fig. 1 ), showing a pattern of variation of ultrasonic pressure over time in accordance with a preferred embodiment of the present invention.
  • the power source and modulator assembly 40 preferably comprises a signal generator 100 which provides a time varying signal which is modulated so as to have a series of relatively high amplitude portions 102 separated il time by a series of typically relatively low amplitude portions 104.
  • Each relatively high amplitude portion 102 preferably corresponds to a cavitation period and preferably has decreasing amplitude over time.
  • the relationship between the time durations of portions 102 and portions 104 is such as to provide a duty cycle between 1: 2 and 1: 50, more preferably between 1: 5 and 1: 30 and most preferably between 1: 10 and 1: 20.
  • the output of signal generator 100 has a frequency in a range of 50 KHz -1000 KHz, more preferably between 100 KHz - 500 KHz and most preferably between 150 KHz - 300 KHz.
  • the output of signal generator 100 is preferably provided to a suitable power amplifier 106, which outputs via impedance matching circuitry 108 to an input of ultrasonic transducer subsystem 10 ( Fig. 1 ), which converts the electrical signal received thereby to a corresponding ultrasonic energy output.
  • the ultrasonic energy output comprises a time varying signal which is modulated correspondingly to the output of signal generator 100 so as to having a series of relatively high amplitude portions 112, corresponding to portions 102, separated in time by a series of typically relatively low amplitude portions 114, corresponding to portions I 04.
  • Relatively low amplitude portions 114 have amplitude that lies below both thresholds 120 and 122.
  • the relationship between the time durations of portions 112 and portions 114 is such as to provide a duty cycle between 1: 2 and 1: 50, more preferably between 1 : 5 and 1 : 30 and most preferably between 1: 10 and 1: 20.
  • the ultrasonic energy output of ultrasonic transducer 10 has a frequency in a range of 50 KHz-1000 KHz, more preferably between 100 KHz-500 KHz and most preferably between 150 KHz-300 KHz.
  • each high amplitude portion 112 is comprised of between 2 and 1000 sequential cycles at an amplitude above the cavitation maintaining threshold 120, more preferably between 25 and 500 sequential cycles at an amplitude above the cavitation maintaining threshold 120 and most preferably between 100 and 300 sequential cycles at an amplitude above the cavitation maintaining threshold 120.
  • Figs. 3A and 3B are simplified pictorial illustrations of the appearance of an operator interface display during normal operation and faulty operation respectively.
  • display 48 typically shows a plurality of target volumes 12 ( Fig. 1 ) within a calculated target region 200, typically delimited by outline representation 52 ( Fig. 1 ).
  • display 48 preferably provides one or more pre-programmed performance messages 202 and status messages 203.
  • target volumes 12 are shown with different shading in order to indicate their treatment status.
  • unshaded target volumes here designated by reference numerals 204
  • a blackened target volume 12 designated by reference numeral 205 is the target volume next in line for cellulite treatment.
  • a partially shaded target volume 206 typically represents a target volume, which has been insufficiently treated to achieve complete cellulite treatment, typically due to insufficient treatment duration.
  • target volumes such as those not to be treated due to insufficient presence of cellulite therein or for other reasons, may be designated by suitable colors or other designations, and are here indicated by reference numerals 208 and 210.
  • Typical performance messages 202 may include "CAVITATION IN PROCESS” and “CELLULITE LYSED IN THIS VOLUME”.
  • Typical status messages 203 may include an indication of the power level, the operating frequency, the number of target volumes 12 within the calculated target region 200 and the number of target volumes 12 which remain to undergo cellulite treatment.
  • Display 48 also preferably includes a graphical cross sectional presentation 212 derived from an ultrasonic image preferably provided by imaging ultrasonic transducer subassembly 29 ( Fig. 1 ).
  • Presentation 212 preferably indicates various tissues in the body in cross section and shows the target volumes 12 in relation thereto.
  • presentation 212 may also provide a visually sensible indication of cavitation within the target volume 12.
  • presentation 212 may also provide schematic representations 213, 214, 215 and 216 of dermis 69, cellulite 66, fascia 70 and deep fat 67, respectively.
  • warning messages 217 may include "BAD ACOUSTIC CONTACT", "TEMPERATURE TOO HIGH".
  • the "TEMPERATURE TOO HIGH” message typically relates to the skin tissue, although it may alternatively or additionally relate to other tissue inside or outside of the target volume of the transducer subsystem 10 ( Fig. 1 ).
  • display 48 may also provided a visual indication of both lysed cellulite and non-lysed cellulite following treatment.
  • the ultrasonic cellulite treatment system comprises a cellulite treatment control computer 44, which outputs to a display 48.
  • Cellulite treatment control computer 44 preferably receives inputs from video camera 46 ( Fig. 1 ) and from a temperature measurement unit 300, which receives temperature threshold settings as well as inputs from skin temperature sensor 34 ( Fig. 1 ) and transducer temperature sensor 36 ( Fig. 1 ).
  • Temperature measurement unit 300 preferably compares the outputs of both sensors 34 and 36 with appropriate threshold settings and provides an indication to cellulite treatment control computer 44 of temperature exceeding either temperature threshold.
  • Cellulite treatment control computer 44 also preferably receives an input from an acoustic contact-monitoring unit 302, which in turn preferably receives an input from a transducer electrical properties measurement unit 304.
  • Transducer electrical properties measurement unit 304 preferably monitors the output of power source and modulator assembly 40 ( Fig. 1 ) applies to ultrasonic therapeutic transducer assembly 13.
  • An output of transducer electrical properties measurement unit 304 is preferably also supplied to a power meter 306, which provides an output to the cellulite treatment control computer 44 and a feedback output to power source and modulator assembly 40.
  • Cellulite treatment control computer 44 also preferably receives inputs from cavitation detection functionality 308, cellulite location identification functionality 310 and lysed cellulite identification functionality 312, all of which receive inputs from ultrasonic reflection analysis functionality 314.
  • Ultrasonic reflection analysis functionality 314 receives ultrasonic imaging inputs from an ultrasonic imaging subsystem 316, which operates ultrasonic imaging transducer 29 ( Fig. 1 ).
  • Cellulite treatment control computer 44 provides outputs to power source and modulator assembly 40, for operating ultrasonic therapeutic transducer assembly 13. and to ultrasonic imaging subsystem 316, for operating ultrasonic imaging transducer 29.
  • a positioning control unit 318 also receives an output from cellulite treatment control computer 44 for driving X-Y-Z positioning assembly 49 ( Fig. 1 ) in order to correctly position transducer subsystem 10, which includes ultrasonic therapeutic transducer assembly 13 and ultrasonic imaging transducer 29.
  • FIGs. 5A , 5B and 5C are together a simplified flowchart illustrating operator steps in carrying out cellulite treatment in accordance with a preferred embodiment of the present invention.
  • an operator preferably draws an outline 50 ( Fig. 1 ) on a patient's body.
  • the operator also adheres stereotactic markers 54 ( Fig. 1 ) to the patient's body and places transducer subsystem 10, bearing transducer marker 56, at a desired location within outline 50.
  • Camera 46 ( Fig. 1 ) captures outline 50 and markers 54 and 56. Preferably, outline 50 and markers 54 and 56 are displayed on display 48 in real time. The output of camera 46 is also preferably supplied to a memory associated with cellulite treatment control computer 44 ( Fig. 1 ).
  • a computerized tracking functionality preferably embodied in cellulite treatment control computer 44 preferably employs the output of camera 46 for computing outline representation 52, which may be displayed for the operator on display 48.
  • the computerized tracking functionality also preferably computes coordinates of target volumes for cellulite treatment, as well as adding up the total volume of tissue sought to undergo cellulite treatment.
  • the operator confirms the locations of markers 54 and 56 on display 48 and the computerized tracking functionality calculates corresponding marker representations 58 and 60.
  • the computerized tracking functionality employs markers 54 and marker representations 58 for continuously maintaining registration of outline 50 with respect to outline representation 52, and thus of target volumes 12 with respect to the patient's body, notwithstanding movements of the patients body during treatment, such as due to breathing or any other movements, such as the patient leaving and returning to the treatment location.
  • the computerized tracking functionality selects an initial target volume to be treated and positioning control unit 318 ( Fig. 4 ), computes the required repositioning of transducer subsystem 10.
  • X-Y-Z positioning assembly 49 repositions transducer subsystem 10 to overlie the selected target volume.
  • the cellulite treatment control computer 44 confirms accurate positioning of transducer subsystem 10 with respect to the selected target volume.
  • the ultrasonic imaging subsystem 316 ( Fig. 4 ) operates ultrasonic imaging transducer 29, causing it to provide an output to ultrasonic reflection analysis functionality 314 for analysis.
  • Cellulite location identification functionality 310 ( Fig. 4 ) is operative to identify dermis 69, cellulite 66, fascia 70 and deep fat 67.
  • an operator may approve the selected target volume and activate the power source and modulator assembly 40 ( Fig. 1 ).
  • Transducer electrical properties measurement unit 304 provides an output to acoustic contact monitoring unit 302, which determines whether sufficient acoustic contact with the patient is present, preferably by analyzing the current and voltage at therapeutic transducer assembly 13.
  • Transducer electrical properties measurement unit 304 provides an output to power meter 306, which computes the average electrical power received by the therapeutic transducer assembly 13. If the average electrical power received by the therapeutic transducer assembly 13 exceeds a predetermined threshold, operation of the power source and modulator assembly 40 may be automatically terminated.
  • Skin temperature sensor 34 measures the current temperature of the skin at transducer subsystem 10 and supplies it to temperature measurement unit 300, which compares the skin temperature to the threshold temperature.
  • transducer temperature sensor 36 measures the current temperature at transducer subsystem 10 and supplies it to temperature measurement unit 300, which compares the transducer subsystem temperature to the threshold temperature.
  • the outputs of temperature measurement unit 300 are supplied to cellulite treatment control computer 44.
  • the ultrasonic imaging subsystem 316 operates ultrasonic imaging transducer 29 and supplies an imaging output, which is analyzed by ultrasonic reflection analysis functionality 314. The result of this analysis is employed for cavitation detection and a cavitation detection output is supplied to cellulite treatment control computer 44.
  • the power source and modulator assembly 40 automatically terminates operation of therapeutic transducer assembly 13. Should none of the following conditions occur, the automatic operation of power source and modulator assembly 40 continues:
  • video camera 46 preferably records the target region and notes whether the transducer subsystem 10 remained stationary during the entire treatment duration of the selected target volume 12. If so, and if none of the aforesaid four conditions took place.
  • cellulite treatment control computer 44 confirms that the selected target volume was treated. The computerized tracking functionality of cellulite treatment control computer 44 then proposes a further target volume 12 to be treated.
  • the selected target volume is designated by cellulite treatment control computer 44 as having been insufficiently treated.
  • multiplicity of target volumes can be treated at various time patterns such as sequential time patterns or partially overlapping time patterns.
  • multiplicity of target volumes may also overlap in space or partially overlap in space.
  • Fig. 6 is a simplified pictorial illustration of the general structure and operation of ultrasonic apoptosis induction apparatus constructed and operative in accordance with a preferred embodiment of the present invention and particularly useful for inducing apoptosis of cellulite and fat. As seen in Fig. 6 ,
  • an ultrasonic energy generator and director such as an ultrasonic transducer subsystem 1010, disposed outside a body, generates ultrasonic energy which, by suitable placement of the transducer subsystem 1010 relative to the body, is directed to a target volume 1012 inside the body and is operative to selectively generally induce apoptosis in cellulite and fat and generally not induce apoptosis in non-cellulite and non-fat tissue in the target volume.
  • a preferred embodiment of ultrasonic energy generator and director useful in the present invention comprises an ultrasonic therapeutic transducer assembly 1013 including a curved phased array 1014 of transducers 1015, typically defining a portion of a sphere or of a cylinder.
  • the transducers 1015 may be of any suitable configuration, shape and distribution.
  • Transducer 1015 is a Langevin type transducer.
  • a preferred Langevin type transducer is shown and includes a pair of piezoelectric elements 1017 separated by a positive contact electrode 1018.
  • a metal bolt 1019 cooperates with a metal disk 1020 and a nut 1021.
  • Negative contact electrodes 1023 are located on both sides of the pair of piezoelectric elements 1017 and are electrically insulated from the bolt 1019 and the disk 1020.
  • transducers 1015 are embedded in a vibration damping material 1024 to avoid mechanical cross talk between transducers 1015.
  • An internal cooling system 1025 may be associated with the transducers 1015.
  • An intermediate element 1026 formed of a material such as polyurethane, which has acoustic impedance similar to that of soft mammalian tissue, generally fills the curvature defined by phased array 1014 and defines a contact surface 1027 for engagement with the body, typically via a suitable coupling gel (not shown).
  • Contact surface 1027 may be planar, but need not be.
  • Suitably modulated AC electrical power is supplied by conductors 1028 to electrodes 1018 and 1023 of transducers 1015 to cause the array 1014 of transducers 1015 to provide a desired focused acoustic energy output.
  • a cellulite imaging ultrasonic transducer subassembly 1029 is incorporated within transducer assembly 1013 and typically comprises a piezoelectric transducer 1030 having conductive surfaces 1031 associated with opposite surfaces thereof.
  • Suitably modulated AC electrical power is supplied by conductors 1032 to conductive surfaces 1031 in order to cause the piezoelectric transducer 1030 to provide an acoustic energy output.
  • Conductors 1032, coupled to conductive surfaces 1031 also provide an imaging output from imaging ultrasonic transducer subassembly 1029.
  • ultrasonic transducer subassembly 1029 may be eliminated.
  • ultrasonic transducer assemblies 1013 may be employed.
  • such transducer assemblies may include multiple Langevin type elements, multi-layered Langevin type elements and Langevin type elements of various shapes and sizes arranged in a phase array.
  • the ultrasonic energy generator and director are combined in transducer assembly 1013.
  • the functions of generating ultrasonic energy and focusing such energy may be provided by distinct devices.
  • a skin temperature sensor 1034 such as an infrared sensor, may be mounted in proximity to the contact surface 1027, as shown in Fig. 6 .
  • a transducer temperature sensor 1036 such as a thermocouple, may also be mounted alongside imaging ultrasonic transducer subassembly 1029.
  • Ultrasonic transducer subsystem 1010 preferably receives suitably modulated electrical power from a power source and modulator assembly 1040, forming part of a control subsystem 1042.
  • Control subsystem 1042 also typically includes a apoptosis induction control computer 1044, having associated therewith a camera 1046, such as a video camera, and a display 1048.
  • a preferred embodiment of power source and modulator assembly 1040 is illustrated in Fig. 7 and described hereinbelow.
  • Ultrasonic transducer subsystem 1010 is preferably positioned automatically or semi-automatically as by an X-Y-Z positioning assembly 1049. Alternatively, ultrasonic transducer subsystem 1010 may be positioned at desired positions by an operator.
  • camera 1046 is operative for imaging a portion of the body on which apoptotic cellulite and fat treatment is to be performed.
  • a picture of the portion of the patient's body viewed by the camera is preferably displayed in real time on display 1048.
  • An operator may designate the outline of a region containing cellulite or fat.
  • designation of this region is effected by an operator marking the skin of a patient with an outline 1050, which outline is imaged by camera 1046 and displayed on display 1048 and is also employed by the apoptosis induction control computer 1044 for controlling the application of ultrasonic energy to locations within the region.
  • a computer calculated representation of the outline may also be displayed on display 1048, as designated by reference numeral 1052.
  • the operator may make a virtual marking on the skin. such as by using a digitizer (not shown), which also may provide computer calculated outline representation 1052 on display 1048.
  • the functionality of the system of the present invention preferably also employs a plurality of markers 1054 which are typically located outside the region containing cellulite and fat, but may be located inside the region designated by outline 1050.
  • Markers 1054 are visually sensible markers, which are clearly seen by camera 1046, captured by camera 1046 and displayed on display 1048.
  • Markers 1054 may be natural anatomic markers, such as distinct portions of the body or alternatively artificial markers such as colored stickers. These markers are preferably employed to assist the system in dealing with deformation of the region nominally defined by outline 1050 due to movement and reorientation of the body.
  • the transducer subsystem 1010 also bears a visible marker 1056 which is also captured by camera 1046 and displayed on display 1048.
  • Markers 1054 and 1056 are typically processed by computer 1044 and may be displayed on display 1048 as respective computed marker representations 1058 and 1060 on display 1048.
  • Fig. 6 illustrates the transducer subsystem 1010 being positioned on the body over a location within a region containing cellulite and fat.
  • Blocks designated by reference numerals 1062 and 1064 show typical portions of a region containing cellulite and fat, respectively before and after apoptotic cellulite and fat treatment in accordance with a preferred embodiment of the invention.
  • Fig. 7 is a simplified block diagram illustration of a preferred power source and modulator assembly 1040 ( Fig. 6 ), showing a pattern of variation of ultrasonic pressure over time in accordance with a preferred embodiment of the present invention.
  • the power source and modulator assembly 1040 preferably comprises a signal generator 1100 which provides a time varying signal which is modulated so as to have a series of relatively high amplitude portions 1102 separated in time by a series of typically relatively low amplitude portions 1104.
  • Each relatively high amplitude portion 1102 preferably corresponds to an apoptosis inducing period and preferably has decreasing amplitude over time.
  • the relationship between the time durations of portions 1102 and portions 1104 is such as to provide a duty cycle between 1: 2 and 1: 50, more preferably between 1 : 5 and 1 : 30 and most preferably between 1 : 10 and 1: 20.
  • the output of signal generator 1100 has a frequency in a range of 50 KHz-1000 KHz, more preferably between 100 KHz-500 KHz and most preferably between 150 KHz-300 KHz.
  • the output of signal generator 1100 is preferably provided to a suitable power amplifier 1106, which outputs via impedance matching circuitry 1108 to an input of ultrasonic transducer subsystem 1010 ( Fig. 6 ), which converts the electrical signal received thereby to a corresponding ultrasonic energy output.
  • the ultrasonic energy output comprises a time varying signal which is modulated correspondingly to the output of signal generator 1100 so as to have a series of relatively high amplitude portions 1112, corresponding to portions 1102, separated in time by a series of typically relatively low amplitude portions 1114, corresponding to portions 1104.
  • Each relatively high amplitude portion 1112 preferably corresponds to an apoptosis period and has amplitude at a target volume 1012 ( Fig. 6 ) in the body, which exceeds an apoptosis threshold 1120 and preferably has decreasing amplitude over time.
  • Relatively low amplitude portions 1114 have amplitudes that lie below both thresholds 1120 and 1122.
  • the relationship between the time durations of portions 1112 and portions 1114 is such as to provide a duty cycle between 1: 2 and 1: 50, more preferably between 1 : 5 and 1: 30 and most preferably between 1: 10 and 1: 20.
  • the ultrasonic energy output of ultrasonic transducer 1010 has a frequency in a range of 50 KHz - 1000 KHz, more preferably between 100 KHz - 500 KHz and most preferably between 150 KHz - 300 KHz.
  • each high amplitude portion 1112 is comprised of between 2 and 1000 sequential cycles at an amplitude above the apoptosis maintaining threshold 1120, more preferably between 25 and 500 sequential cycles at an amplitude above the apoptosis threshold 1120 and most preferably between 100 and 300 sequential cycles at an amplitude above the apoptosis threshold 1120.
  • Figs. 8A and 8B are simplified pictorial illustrations of the appearance of an operator interface display during normal operation and faulty operation respectively.
  • display 1048 typically shows a plurality of target volumes 1012 ( Fig. 6 ) within a calculated target region 1200, typically delimited by outline representation 1052 ( Fig. 6 ). Additionally, display 1048 preferably provides one or more pre-programmed performance messages 1202 and status messages 1203.
  • target volumes 1012 are shown with different shading in order to indicate their treatment status.
  • unshaded target volumes here designated by reference numerals 1204
  • a blackened target volume 1012 designated by reference numeral 1205 is the target volume next in line for apoptotic cellulite and fat treatment.
  • a partially shaded target volume 1206 typically represents a target volume, which has been insufficiently treated to achieve complete apoptotic cellulite and fat treatment, typically due to insufficient treatment duration.
  • target volumes such as those not to be treated due to insufficient presence of cellulite or fat therein or for other reasons, may be designated by suitable colors or other designations, and are here indicated by reference numerals 1208 and 1210.
  • Typical performance messages 1202 may include "APOPTOSIS IN PROCESS” and "APOPTOSIS INDUCED IN THIS VOLUME”.
  • Typical status messages 1203 may include an indication of the power level, the operating frequency, the number of target volumes 1012 within the calculated target region 1200 and the number of target volumes 1012 which remain to undergo apoptotic cellulite and fat treatment.
  • Display 1048 also preferably includes a graphical cross sectional presentation 1212 derived from an ultrasonic image preferably provided by imaging ultrasonic transducer subassembly 1029 ( Fig. 6 ).
  • Presentation 1212 preferably indicates various tissues in the body in cross section and shows the target volumes 1012 in relation thereto.
  • presentation 1212 may also provide a visually sensible indication of apoptosis inducement within the target volume 1012.
  • presentation 1212 may also provide schematic representations 1213. 1214. 1215 and 1216 of dermis 1069, cellulite 1066, fascia 1070 and fat 1067, respectively.
  • warning messages 1217 may include "BAD ACOUSTIC CONTACT", "TEMPERATURE TOO HIGH".
  • the "TEMPERATURE TOO HIGH” message typically relates to the skin tissue, although it may alternatively or additionally relate to other tissue inside or outside of the target volume of the transducer subsystem 1010 ( Fig. 6 ).
  • the ultrasonic apoptosis induction apparatus comprises an apoptosis control computer 1044, which outputs to a display 1048.
  • Apoptosis control computer 1044 preferably receives inputs from video camera 1046 ( Fig. 6 ) and from a temperature measurement unit 1300, which receives temperature threshold settings as well as inputs from skin temperature sensor 1034 ( Fig. 6 ) and transducer temperature sensor 1036 ( Fig. 6 ).
  • Temperature measurement unit 1300 preferably compares the outputs of both sensors 1034 and 1036 with appropriate threshold settings and provides an indication to apoptosis control computer 1044 of temperature exceeding either temperature thresholds.
  • Apoptosis control computer 1044 also preferably receives an input from an acoustic contact-monitoring unit 1302, which in turn preferably receives an input from a transducer electrical properties measurement unit 1304.
  • Transducer electrical properties measurement unit 1304 preferably monitors the output of power source and modulator assembly 1040 ( Fig. 6 ) applies to ultrasonic therapeutic transducer assembly 1013.
  • An output of transducer electrical properties measurement unit 1304 is preferably also supplied to a power meter 1306, which provides an output to the apoptosis control computer 1044 and a feedback output to power source and modulator assembly 1040.
  • Apoptosis control computer 1044 also preferably receives inputs from apoptosis detection functionality 1308, treatment location identification functionality 1310 and apoptosis tissue identification functionality 1312, all of which receive inputs from ultrasonic reflection analysis functionality 1314.
  • Ultrasonic reflection analysis functionality 1314 receives ultrasonic imaging inputs from an ultrasonic imaging subsystem 1316. which operates ultrasonic imaging transducer subassembly 1029 ( Fig. 6 ).
  • Apoptosis control computer 1044 provides outputs to power source and modulator assembly 1040, for operating ultrasonic therapeutic transducer assembly 1013, and to ultrasonic imaging subsystem 1316, for operating ultrasonic imaging transducer subassembly 1029.
  • a positioning control unit 1318 also receives an output from apoptosis control computer 1044 for driving X-Y-Z positioning assembly 1049 ( Fig. 6 ) in order to correctly position transducer subsystem 1010, which includes ultrasonic therapeutic transducer assembly 1014 and ultrasonic imaging transducer subassembly 1029.
  • FIGs. 10A , 10B and 10C are together a simplified flowchart illustrating operator steps in carrying out apoptotic cellulite and fat treatment in accordance with a preferred embodiment of the present invention.
  • an operator preferably draws an outline 1050 ( Fig. 6 ) on a patient's body.
  • the operator also adheres stereotactic markers 1054 ( Fig. 6 ) to the patient's body and places transducer subsystem 1010, bearing transducer marker 1056, at a desired location within outline 1050.
  • Camera 1046 captures outline 1050 and markers 1054 and 1056.
  • outline 1050 and markers 1054 and 1056 are displayed on display 1048 in real time.
  • the output of camera 1046 is also preferably supplied to a memory associated with apoptosis control computer 1044 ( Fig. 6 ).
  • a computerized tracking functionality preferably embodied in apoptosis control computer 1044 preferably employs the output of camera 1046 for computing outline representation 1052, which may be displayed for the operator on display 1048.
  • the computerized tracking functionality also preferably computes coordinates of target volumes for apoptotic cellulite and fat treatment, as well as summing the total volume of tissue sought to undergo apoptotic cellulite and fat treatment.
  • the operator confirms the locations of markers 1054 and 1056 on display 1048 and the computerized tracking functionality calculates corresponding marker representations 1058 and 1060.
  • the computerized tracking functionality employs markers 1054 and marker representations 1058 for continuously maintaining registration of outline 1050 with respect to outline representation 1052, and thus of target volumes 1012 with respect to the patient's body, notwithstanding movements of the patients body during treatment, such as due to breathing or any other movements, such as the patient leaving and returning to the treatment location.
  • the computerized tracking functionality selects an initial target volume to be treated and positioning control unit 1318 ( Fig. 9 ), computes the required repositioning of transducer subsystem 1010.
  • X-Y-Z positioning assembly 1049 repositions transducer subsystem 1010 to overlie the selected target volume.
  • the apoptosis control computer 1044 confirms accurate positioning of transducer subsystem 1010 with respect to the selected target volume.
  • the ultrasonic imaging subsystem 1316 ( Fig. 9 ) operates ultrasonic imaging transducer subassembly 1029, causing it to provide an output to ultrasonic reflection analysis functionality 1314 for analysis.
  • Treatment location identification functionality 1310 ( Fig. 9 ) is operative to identify dermis 1069, cellulite 1066, fascia 1070 and fat 1067.
  • an operator may approve the selected target volume and activate the power source and modulator assembly 1040 ( Fig. 6 ).
  • Transducer electrical properties measurement unit 1304 provides an output to acoustic contact monitoring unit 1302, which determines whether sufficient acoustic contact with the patient is present, preferably by analyzing the current and voltage at therapeutic transducer assembly 1013.
  • Transducer electrical properties measurement unit 1304 provides an output to power meter 1306, which computes the average electrical power received by the therapeutic transducer assembly 1013. If the average electrical power received by the therapeutic transducer assembly 1013 exceeds a predetermined threshold, operation of the power source and modulator assembly 1040 may be automatically terminated.
  • Skin temperature sensor 1034 measures the current temperature of the skin at transducer subsystem 1010 and supplies it to temperature measurement unit 1300. which compares the skin temperature to the threshold temperature.
  • transducer temperature sensor 1036 measures the current temperature at transducer subsystem 1010 and supplies it to temperature measurement unit 1300, which compares the transducer subsystem temperature to the threshold temperature.
  • the outputs of temperature measurement unit 1300 are supplied to apoptosis control computer 1044.
  • the ultrasonic imaging subsystem 1316 operates ultrasonic imaging ) transducer subassembly 1029 and receives an imaging output, which is analyzed by ultrasonic reflection analysis functionality 1314. The result of this analysis is employed for apoptosis detection and an apoptosis detection output is supplied to apoptosis control computer 1044.
  • the power source and modulator assembly 1040 automatically terminates operation of therapeutic transducer assembly 1013. Should none of the following conditions occur, the automatic operation of power source and modulator assembly 1040 continues:
  • video camera 1046 preferably records the target region and notes whether the transducer subsystem 1010 remained stationary during the entire treatment duration of the selected target volume 1012. If so, and if none of the aforesaid four conditions took place, apoptosis control computer 1044 confirms that the selected target volume was treated. The computerized tracking functionality of apoptosis control computer 1044 then proposes a further target volume 1012 to be treated.
  • the selected target volume is designated by apoptosis control computer 1044 as having been insufficiently treated.
  • multiplicity of target volumes can be treated at various time patterns such as sequential time patterns or partially overlapping time patterns.
  • multiplicity of target volumes may also overlap in space or partially overlap in space.
  • FIGS. 11A and 11B are together a simplified flowchart illustrating steps in carrying out unit by unit tracking within a time variable three dimensional outline in accordance with a preferred embodiment of the present invention.
  • Figs 11A and 11B The functionality described hereinbelow and shown in Figs 11A and 11B is particularly useful as part of the functionality described hereinabove with reference to Figs. 1 and 6 wherein motion of markers 54, 56, 1054 and 1056 is tracked and employed to track the target volumes notwithstanding motion of the body. It is appreciated that this functionality is also applicable for many other types of computerized medical treatment and diagnosis, hereinafter collectively referred to as treatment, employing machine vision and even to non medical applications wherein machine vision is used to track multiple relatively moving elements.
  • an operator initiates a process of outline detection typically by drawing on a computer screen a line which encompasses the entire outline to be detected.
  • the image so circumscribed is captured.
  • Various color filters are applied to the captured image to provide maximum contrast of the outline with respect to its background and to reduce noise.
  • a threshold is applied to the enhanced contrast and noise-reduced result of the filtering.
  • the outline is then homogenized and any remaining marker indications are removed, thereby producing a clean, unambiguous outline presentation.
  • the clean unambiguous outline presentation is overlaid upon a video image of the outline and the image content interior thereof. If the overlay is not sufficiently congruent with the video image, manual intervention may take place.
  • the operator designates the locations of those markers, inside or outside of the outline, which are to be used in tracking.
  • the marker which is attached to the ultrasonic transducer subsystem is specifically designated as such and may contain information as to the geometrical and other operational characteristics thereof, such as those relating to the size and relative position of its characteristic target volume. For each such designated marker the geometrical center and the geometrical configuration of the marker are noted.
  • a geometrical center of the outline is calculated and the position of the geometrical center of each marker relative to the geometrical center of the outline is noted.
  • changes in the observed geometrical configuration of each marker indicate tilting of that marker from a nominal orientation thereof.
  • variations in the three dimensional configuration of that surface may be monitored.
  • a calculation is made to define a virtual grid of target volumes superimposed over the three-dimensional surface, the grid units preferably being the size of the target volumes characteristic of the ultrasonic transducer subsystem.
  • the grid units may or may not be selected to be partially mutually overlapping. Any suitable grid unit shape may be employed.
  • the system then displays a desired position in three dimensions for the ultrasonic transducer subsystem for treatment of a first target volume.
  • a visual and/or other confirmation of correct positioning is provided to the operator and the operator is enabled to commence treatment of that target volume.
  • the system designates the grid point as "treated target volume" and checks for more target volumes to be treated.
  • the system again, checks for changes in the observed geometrical configuration of each marker indicate tilting of that marker from a nominal orientation thereof.
  • variations in the three dimensional configuration of that surface may be monitored.
  • a calculation is made to define a new virtual grid of target volumes superimposed over the three-dimensional surface, the grid units are in one to one correspondence with the previous grid, and all data on treated grid points is kept
  • the system then displays a desired position in three dimensions for a subsequent target volume for further operation in a similar manner.
  • the subsequent target volume is selected by the operator.
  • the operator scans the region within the outline and the system ensures that treatment is not applied to grid units which have already been treated or do not require treatment.
  • a software object code for the computational tracking functionality includes the following steps:
  • the software components of the present invention may, if desired, be implemented in ROM (read-only memory) form.
  • the software components may, generally, be implemented in hardware, if desired, using conventional techniques.

Claims (6)

  1. Gerät zum Lysieren von Cellulite, wobei das Gerät umfasst:
    ein Richtgerät (10) für gebündelte Ultraschallenergie, das gebündelte Ultraschall-energie auf ein Zielvolumen (12) in einem Bereich eines Körpers richtet, der Cellulite (66) enthält, wobei das Richtgerät für gebündelte Ultraschallenergie eine Vielzahl von Langevin-Ultraschallwandlern umfasst; und
    einen Modulator (40), der dazu eingerichtet ist, mit dem Energierichtgerät zusammenzuarbeiten, um gebündelte Ultraschallenergie zu erzeugen, die eine Abfolge von Abschnitten relativ hoher Amplitude umfasst, die zeitlich durch eine Abfolge von Abschnitten relativ geringer Amplitude bei einem Tastverhältnis zwischen 1:2 bis 1:50 getrennt sind, wobei jeder Abschnitt hoher Amplitude einer Kavitationsperiode entspricht, um so wahlweise die Cellulite in dem Zielvolumen zu lysieren und im wesentlichen das Gewebe ohne Cellulite (67, 68, 69, 70) in dem Zielvolumen nicht zu lysieren.
  2. Gerät zum Lysieren von Cellulite nach Anspruch 1, bei dem das Richtgerät betätigt werden kann, um im wesentlichen eine Lysis von Gewebe außerhalb des Zielvolumens zu verhindern.
  3. Gerät zum Lysieren von Cellulite nach Anspruch 1 oder 2, weiterhin umfassend: eine Ultraschallabbildungseinrichtung (29), die eine Ultraschallabbildung des Bereiches wenigstens teilweise zeitgleich damit bereitstellt, dass das Richtgerät die gebündelte Ultraschallenergie auf das Zielvolumen richtet.
  4. Gerät zum Hervorrufen von Apoptose in Cellulite und Fett, wobei das Gerät umfasst:
    ein Richtgerät (1010) für gebündelte Ultraschallenergie, das gebündelte Ultraschallenergie auf ein Zielvolumen (1012) in einem Bereich eines Körpers richtet, der Cellulite (1066) und Fett (1067) enthält, wobei das Richtgerät für gebündelte Ultraschallenergie eine Vielzahl von Langevin-Ultraschallwandlern umfasst; und
    einen Modulator (1040), der dazu eingerichtet ist, mit dem Energierichtgerät zusammenzuwirken, um gebündelte Ultraschallenergie zu erzeugen, die eine Abfolge von Abschnitten relativ hoher Amplitude umfasst, die zeitlich durch eine Abfolge von Abschnitten relativ geringer Amplitude bei einem Tastverhältnis zwischen 1:2 bis 1:50 getrennt sind, um so wahlweise Apoptose in der Cellulite und dem Fett in dem Zielvolumen hervorzurufen und im wesentlichen keine Apoptose in dem Gewebe ohne Cellulite und ohne Fett in dem Zielvolumen hervorzurufen.
  5. Gerät zum Hervorrufen von Apoptose in Cellulite und Fett nach Anspruch 4, bei dem das Richtgerät betrieben werden kann, um im wesentlichen ein Hervorrufen von Apoptose in dem Gewebe außerhalb des Zielvolumens zu verhindern.
  6. Gerät zum Hervorrufen von Apoptose in Cellulite und Fett nach Anspruch 4 oder Anspruch 5, weiterhin umfassend:
    eine Ultraschallabbildungseinrichtung (1029), die eine Ultraschallabbildung des Bereiches wenigstens teilweise zeitgleich damit bereitstellt, dass das Richtgerät die gebündelte Ultraschallenergie auf das Zielvolumen richtet.
EP02743588.2A 2002-06-25 2002-06-25 Vorrichtung für die körperästhetik Expired - Lifetime EP1538980B1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2002/000510 WO2004000116A1 (en) 2002-06-25 2002-06-25 Devices and methodologies useful in body aesthetics

Publications (3)

Publication Number Publication Date
EP1538980A1 EP1538980A1 (de) 2005-06-15
EP1538980A4 EP1538980A4 (de) 2008-12-03
EP1538980B1 true EP1538980B1 (de) 2017-01-18

Family

ID=29798301

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02743588.2A Expired - Lifetime EP1538980B1 (de) 2002-06-25 2002-06-25 Vorrichtung für die körperästhetik

Country Status (10)

Country Link
US (2) US7331951B2 (de)
EP (1) EP1538980B1 (de)
JP (1) JP2005530548A (de)
KR (1) KR100923717B1 (de)
CN (1) CN1662177A (de)
AU (2) AU2002345319B2 (de)
BR (1) BR0215785A (de)
CA (1) CA2490725A1 (de)
IL (1) IL165909A (de)
WO (1) WO2004000116A1 (de)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10238894B2 (en) 2004-10-06 2019-03-26 Guided Therapy Systems, L.L.C. Energy based fat reduction
US10245450B2 (en) 2004-10-06 2019-04-02 Guided Therapy Systems, Llc Ultrasound probe for fat and cellulite reduction
US10252086B2 (en) 2004-10-06 2019-04-09 Guided Therapy Systems, Llc Ultrasound probe for treatment of skin
US10265550B2 (en) 2004-10-06 2019-04-23 Guided Therapy Systems, L.L.C. Ultrasound probe for treating skin laxity
US11590370B2 (en) 2004-09-24 2023-02-28 Guided Therapy Systems, Llc Rejuvenating skin by heating tissue for cosmetic treatment of the face and body
US11969609B2 (en) 2022-12-05 2024-04-30 Ulthera, Inc. Devices and methods for multi-focus ultrasound therapy

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6104959A (en) 1997-07-31 2000-08-15 Microwave Medical Corp. Method and apparatus for treating subcutaneous histological features
US6050943A (en) 1997-10-14 2000-04-18 Guided Therapy Systems, Inc. Imaging, therapy, and temperature monitoring ultrasonic system
US7914453B2 (en) 2000-12-28 2011-03-29 Ardent Sound, Inc. Visual imaging system for ultrasonic probe
US7347855B2 (en) * 2001-10-29 2008-03-25 Ultrashape Ltd. Non-invasive ultrasonic body contouring
JP4727903B2 (ja) * 2001-01-03 2011-07-20 ウルトラシェイプ リミティド 非侵襲性超音波体型輪郭形成
US20030069569A1 (en) 2001-08-29 2003-04-10 Burdette Everette C. Ultrasound device for treatment of intervertebral disc tissue
US7762964B2 (en) * 2001-12-10 2010-07-27 Candela Corporation Method and apparatus for improving safety during exposure to a monochromatic light source
EP1829496A2 (de) * 2001-12-10 2007-09-05 Inolase 2002 Ltd. Verfahren und Vorrichtung zur augensicheren Haarentfernung
US7762965B2 (en) * 2001-12-10 2010-07-27 Candela Corporation Method and apparatus for vacuum-assisted light-based treatments of the skin
US7935139B2 (en) * 2001-12-10 2011-05-03 Candela Corporation Eye safe dermatological phototherapy
EP1627662B1 (de) * 2004-06-10 2011-03-02 Candela Corporation Apparat für vakuumunterstützte dermatologische Phototherapien
US7331951B2 (en) * 2002-06-25 2008-02-19 Ultrashape Inc. Devices and methodologies useful in body aesthetics
US7740600B2 (en) * 2002-08-02 2010-06-22 Candela Corporation Apparatus and method for inhibiting pain signals transmitted during a skin related medical treatment
US8235909B2 (en) 2004-05-12 2012-08-07 Guided Therapy Systems, L.L.C. Method and system for controlled scanning, imaging and/or therapy
US9011336B2 (en) 2004-09-16 2015-04-21 Guided Therapy Systems, Llc Method and system for combined energy therapy profile
US7824348B2 (en) 2004-09-16 2010-11-02 Guided Therapy Systems, L.L.C. System and method for variable depth ultrasound treatment
US7393325B2 (en) * 2004-09-16 2008-07-01 Guided Therapy Systems, L.L.C. Method and system for ultrasound treatment with a multi-directional transducer
US20120165668A1 (en) 2010-08-02 2012-06-28 Guided Therapy Systems, Llc Systems and methods for treating acute and/or chronic injuries in soft tissue
US8535228B2 (en) 2004-10-06 2013-09-17 Guided Therapy Systems, Llc Method and system for noninvasive face lifts and deep tissue tightening
US8444562B2 (en) 2004-10-06 2013-05-21 Guided Therapy Systems, Llc System and method for treating muscle, tendon, ligament and cartilage tissue
US8690779B2 (en) 2004-10-06 2014-04-08 Guided Therapy Systems, Llc Noninvasive aesthetic treatment for tightening tissue
US11883688B2 (en) 2004-10-06 2024-01-30 Guided Therapy Systems, Llc Energy based fat reduction
KR101328103B1 (ko) * 2004-10-06 2013-11-13 가이디드 테라피 시스템스, 엘.엘.씨. 비침습적 미용 증진 방법 및 시스템
IL301311A (en) * 2004-10-06 2023-05-01 Guided Therapy Systems Llc Ultrasound system for medical treatment
US7530356B2 (en) 2004-10-06 2009-05-12 Guided Therapy Systems, Inc. Method and system for noninvasive mastopexy
KR20130080477A (ko) 2004-10-06 2013-07-12 가이디드 테라피 시스템스, 엘.엘.씨. 초음파 치료 시스템
US7758524B2 (en) 2004-10-06 2010-07-20 Guided Therapy Systems, L.L.C. Method and system for ultra-high frequency ultrasound treatment
US11235179B2 (en) 2004-10-06 2022-02-01 Guided Therapy Systems, Llc Energy based skin gland treatment
US20060111744A1 (en) 2004-10-13 2006-05-25 Guided Therapy Systems, L.L.C. Method and system for treatment of sweat glands
US11724133B2 (en) 2004-10-07 2023-08-15 Guided Therapy Systems, Llc Ultrasound probe for treatment of skin
US11207548B2 (en) 2004-10-07 2021-12-28 Guided Therapy Systems, L.L.C. Ultrasound probe for treating skin laxity
CN101146574A (zh) * 2005-02-06 2008-03-19 超形态公司 非热的声波组织改变
US8218477B2 (en) * 2005-03-31 2012-07-10 Alcatel Lucent Method of detecting wireless network faults
JP4695188B2 (ja) 2005-04-25 2011-06-08 アーデント サウンド， インコーポレイテッド コンピュータ周辺機器の安全性を向上させるための方法および装置
US8801764B2 (en) * 2005-05-05 2014-08-12 Biolitec Pharma Marketing Ltd Cosmetic laser treatment device and method for localized lipodystrophies and flaccidity
US20090093737A1 (en) * 2007-10-09 2009-04-09 Cabochon Aesthetics, Inc. Ultrasound apparatus with treatment lens
US9358033B2 (en) 2005-09-07 2016-06-07 Ulthera, Inc. Fluid-jet dissection system and method for reducing the appearance of cellulite
US10548659B2 (en) 2006-01-17 2020-02-04 Ulthera, Inc. High pressure pre-burst for improved fluid delivery
US7967763B2 (en) * 2005-09-07 2011-06-28 Cabochon Aesthetics, Inc. Method for treating subcutaneous tissues
US9011473B2 (en) 2005-09-07 2015-04-21 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9486274B2 (en) 2005-09-07 2016-11-08 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US8518069B2 (en) 2005-09-07 2013-08-27 Cabochon Aesthetics, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US8057408B2 (en) * 2005-09-22 2011-11-15 The Regents Of The University Of Michigan Pulsed cavitational ultrasound therapy
US10219815B2 (en) 2005-09-22 2019-03-05 The Regents Of The University Of Michigan Histotripsy for thrombolysis
US20070083120A1 (en) * 2005-09-22 2007-04-12 Cain Charles A Pulsed cavitational ultrasound therapy
US9248317B2 (en) 2005-12-02 2016-02-02 Ulthera, Inc. Devices and methods for selectively lysing cells
US7885793B2 (en) 2007-05-22 2011-02-08 International Business Machines Corporation Method and system for developing a conceptual model to facilitate generating a business-aligned information technology solution
US20090048514A1 (en) * 2006-03-09 2009-02-19 Slender Medical Ltd. Device for ultrasound monitored tissue treatment
US9107798B2 (en) * 2006-03-09 2015-08-18 Slender Medical Ltd. Method and system for lipolysis and body contouring
US7828734B2 (en) * 2006-03-09 2010-11-09 Slender Medical Ltd. Device for ultrasound monitored tissue treatment
EP1844750A1 (de) * 2006-04-12 2007-10-17 Lain Electronic S.r.L. Vorrichtung zur Behandlung von Zellulitis und Fettgewebe
US20070249938A1 (en) * 2006-04-20 2007-10-25 Donald J. Shields Systems, devices, and methods employing therapeutic ultrasound of living tissues
US20090171253A1 (en) * 2006-09-06 2009-07-02 Cutera, Inc. System and method for dermatological treatment using ultrasound
US20080183110A1 (en) * 2006-09-06 2008-07-31 Davenport Scott A Ultrasound system and method for hair removal
US20080195000A1 (en) * 2006-09-06 2008-08-14 Spooner Gregory J R System and Method for Dermatological Treatment Using Ultrasound
US9566454B2 (en) 2006-09-18 2017-02-14 Guided Therapy Systems, Llc Method and sysem for non-ablative acne treatment and prevention
US8192474B2 (en) 2006-09-26 2012-06-05 Zeltiq Aesthetics, Inc. Tissue treatment methods
US9132031B2 (en) 2006-09-26 2015-09-15 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
US20080077201A1 (en) * 2006-09-26 2008-03-27 Juniper Medical, Inc. Cooling devices with flexible sensors
US9241683B2 (en) 2006-10-04 2016-01-26 Ardent Sound Inc. Ultrasound system and method for imaging and/or measuring displacement of moving tissue and fluid
US10183183B2 (en) * 2007-04-13 2019-01-22 Acoustic Medsystems, Inc. Acoustic applicators for controlled thermal modification of tissue
WO2008131306A1 (en) 2007-04-19 2008-10-30 The Foundry, Inc. Systems and methods for creating an effect using microwave energy to specified tissue
CN101711134B (zh) 2007-04-19 2016-08-17 米勒玛尔实验室公司 对组织施加微波能量的系统及在组织层中产生组织效果的系统
EP2767308B1 (de) 2007-04-19 2016-04-13 Miramar Labs, Inc. Vorrichtungen und Systeme zur nichtinvasiven Verabreichung von Mikrowellentherapie
EP3391844A1 (de) * 2007-04-19 2018-10-24 Miramar Labs, Inc. Vorrichtung zur verringerung der schweissproduktion
US8688228B2 (en) * 2007-04-19 2014-04-01 Miramar Labs, Inc. Systems, apparatus, methods and procedures for the noninvasive treatment of tissue using microwave energy
US9241763B2 (en) * 2007-04-19 2016-01-26 Miramar Labs, Inc. Systems, apparatus, methods and procedures for the noninvasive treatment of tissue using microwave energy
US20150174388A1 (en) 2007-05-07 2015-06-25 Guided Therapy Systems, Llc Methods and Systems for Ultrasound Assisted Delivery of a Medicant to Tissue
ES2699477T3 (es) 2007-05-07 2019-02-11 Guided Therapy Systems Llc Métodos y sistemas para acoplar y enfocar energía acústica usando un miembro acoplador
TWI526233B (zh) * 2007-05-07 2016-03-21 指導治療系統股份有限公司 利用聲波能量調製藥劑輸送及效能之系統
US20080287839A1 (en) 2007-05-18 2008-11-20 Juniper Medical, Inc. Method of enhanced removal of heat from subcutaneous lipid-rich cells and treatment apparatus having an actuator
US8523927B2 (en) 2007-07-13 2013-09-03 Zeltiq Aesthetics, Inc. System for treating lipid-rich regions
US8285390B2 (en) 2007-08-21 2012-10-09 Zeltiq Aesthetics, Inc. Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue
US7740651B2 (en) * 2007-09-28 2010-06-22 Candela Corporation Vacuum assisted treatment of the skin
US20090093723A1 (en) * 2007-10-05 2009-04-09 Cabochon Aesthetics, Inc. Ultrasound device including dispenser
US8439940B2 (en) 2010-12-22 2013-05-14 Cabochon Aesthetics, Inc. Dissection handpiece with aspiration means for reducing the appearance of cellulite
US20090093738A1 (en) * 2007-10-09 2009-04-09 Cabochon Aesthetics, Inc. Device and method for monitoring a treatment area
US20090099484A1 (en) * 2007-10-11 2009-04-16 Yehuda Zadok Coating of polyurethane membrane
US20100274161A1 (en) * 2007-10-15 2010-10-28 Slender Medical, Ltd. Implosion techniques for ultrasound
EP2209526A1 (de) * 2007-11-15 2010-07-28 Koninklijke Philips Electronics N.V. Verfahren und vorrichtung zur positionsverfolgung eines therapeutischen ultraschallkopfes
ES2471971T3 (es) 2007-12-12 2014-06-27 Miramar Labs, Inc. Sistema y aparato para el tratamiento no invasivo de tejido utilizando energía de microondas
CA2713939C (en) * 2008-02-01 2017-12-05 Alma Lasers Ltd. Apparatus and method for selective ultrasonic damage of adipocytes
CA3206234A1 (en) 2008-06-06 2009-12-10 Ulthera, Inc. A system and method for cosmetic treatment and imaging
US20100049098A1 (en) * 2008-08-20 2010-02-25 Avi Shalgi Automatic acoustic treatment device
WO2010029555A1 (en) * 2008-09-12 2010-03-18 Slender Medical, Ltd. Virtual ultrasonic scissors
EP2346428B1 (de) 2008-09-25 2019-11-06 Zeltiq Aesthetics, Inc. Behandlungsplanungssysteme und verfahren zur körperformung
US8876799B1 (en) 2008-10-14 2014-11-04 Alfredo Ernesto Hoyos Ariza Vaser assisted high definition liposculpture
US8167868B1 (en) * 2008-10-14 2012-05-01 Alfredo Ernesto Hoyos Ariza VASER assisted high definition liposculpture
US9888933B1 (en) 2008-10-14 2018-02-13 Alfredo Ernesto Hoyos Ariza Vaser assisted high definition liposculpture
US10980925B1 (en) 2008-10-14 2021-04-20 A Hoyos Llc High definition liposculpture
US20100106063A1 (en) * 2008-10-29 2010-04-29 Cabochon Aesthetics, Inc. Ultrasound Enhancing Target for Treating Subcutaneous Tissue
US8357150B2 (en) 2009-07-20 2013-01-22 Syneron Medical Ltd. Method and apparatus for fractional skin treatment
US8603073B2 (en) 2008-12-17 2013-12-10 Zeltiq Aesthetics, Inc. Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells
DE102009007868B3 (de) * 2009-02-06 2010-05-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Sensorsystem und Verfahren zur bildgebenden Erfassung eines Objektes
CN101559261B (zh) * 2009-03-13 2012-01-04 北京汇福康医疗技术有限公司 一种超声波减脂塑形机
US8167280B2 (en) * 2009-03-23 2012-05-01 Cabochon Aesthetics, Inc. Bubble generator having disposable bubble cartridges
US20100256596A1 (en) * 2009-04-07 2010-10-07 Cabochon Aesthetics, Inc. Fiber growth promoting implants for reducing the appearance of cellulite
ES2916830T3 (es) 2009-04-30 2022-07-06 Zeltiq Aesthetics Inc Dispositivo para eliminar el calor de las células subcutáneas ricas en lípidos
US8298163B1 (en) 2009-05-01 2012-10-30 Body Beam Research Inc. Non-invasive ultrasonic soft-tissue treatment apparatus
US8206306B2 (en) * 2009-05-07 2012-06-26 Hitachi Aloka Medical, Ltd. Ultrasound systems and methods for orthopedic applications
US20100286519A1 (en) * 2009-05-11 2010-11-11 General Electric Company Ultrasound system and method to automatically identify and treat adipose tissue
US20100286518A1 (en) * 2009-05-11 2010-11-11 General Electric Company Ultrasound system and method to deliver therapy based on user defined treatment spaces
US20100286520A1 (en) * 2009-05-11 2010-11-11 General Electric Company Ultrasound system and method to determine mechanical properties of a target region
US9358064B2 (en) 2009-08-07 2016-06-07 Ulthera, Inc. Handpiece and methods for performing subcutaneous surgery
US11096708B2 (en) 2009-08-07 2021-08-24 Ulthera, Inc. Devices and methods for performing subcutaneous surgery
US9061131B2 (en) * 2009-08-17 2015-06-23 Histosonics, Inc. Disposable acoustic coupling medium container
WO2011028603A2 (en) 2009-08-26 2011-03-10 The Regents Of The University Of Michigan Micromanipulator control arm for therapeutic and imaging ultrasound transducers
US9901753B2 (en) * 2009-08-26 2018-02-27 The Regents Of The University Of Michigan Ultrasound lithotripsy and histotripsy for using controlled bubble cloud cavitation in fractionating urinary stones
US8539813B2 (en) 2009-09-22 2013-09-24 The Regents Of The University Of Michigan Gel phantoms for testing cavitational ultrasound (histotripsy) transducers
US8715186B2 (en) 2009-11-24 2014-05-06 Guided Therapy Systems, Llc Methods and systems for generating thermal bubbles for improved ultrasound imaging and therapy
US9314368B2 (en) 2010-01-25 2016-04-19 Zeltiq Aesthetics, Inc. Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants, and associates devices, systems and methods
US8676338B2 (en) 2010-07-20 2014-03-18 Zeltiq Aesthetics, Inc. Combined modality treatment systems, methods and apparatus for body contouring applications
US9504446B2 (en) 2010-08-02 2016-11-29 Guided Therapy Systems, Llc Systems and methods for coupling an ultrasound source to tissue
US8857438B2 (en) 2010-11-08 2014-10-14 Ulthera, Inc. Devices and methods for acoustic shielding
CN103260536B (zh) * 2010-12-09 2016-06-08 日立阿洛卡医疗株式会社 超声治疗装置及其控制方法
US8425490B2 (en) 2011-06-28 2013-04-23 Alfredo Ernesto Hoyos Ariza Dynamic liposculpting method
WO2013009784A2 (en) 2011-07-10 2013-01-17 Guided Therapy Systems, Llc Systems and method for accelerating healing of implanted material and/or native tissue
WO2013012641A1 (en) 2011-07-11 2013-01-24 Guided Therapy Systems, Llc Systems and methods for coupling an ultrasound source to tissue
US9314301B2 (en) 2011-08-01 2016-04-19 Miramar Labs, Inc. Applicator and tissue interface module for dermatological device
US9144694B2 (en) 2011-08-10 2015-09-29 The Regents Of The University Of Michigan Lesion generation through bone using histotripsy therapy without aberration correction
FR2982769B1 (fr) * 2011-11-18 2016-02-05 Lpa Corp Dispositif de traitement de la cellulite
NZ750379A (en) 2012-01-12 2022-10-28 Auxilium Int Holdings Inc Clostridium histolyticum enzymes and methods for the use thereof
US9049783B2 (en) 2012-04-13 2015-06-02 Histosonics, Inc. Systems and methods for obtaining large creepage isolation on printed circuit boards
US9263663B2 (en) 2012-04-13 2016-02-16 Ardent Sound, Inc. Method of making thick film transducer arrays
WO2013166019A1 (en) 2012-04-30 2013-11-07 The Regents Of The University Of Michigan Ultrasound transducer manufacturing using rapid-prototyping method
US20150209551A1 (en) 2012-08-15 2015-07-30 Everette C. Burdette Mri compatible ablation catheter system incorporating directional high-intensity ultrasound for treatment
US9510802B2 (en) 2012-09-21 2016-12-06 Guided Therapy Systems, Llc Reflective ultrasound technology for dermatological treatments
EP2903688A4 (de) 2012-10-05 2016-06-15 Univ Michigan Blaseninduziertes farbdoppler-feedback während einer histotripsie
CN204017181U (zh) 2013-03-08 2014-12-17 奥赛拉公司 美学成像与处理系统、多焦点处理系统和执行美容过程的系统
US9545523B2 (en) 2013-03-14 2017-01-17 Zeltiq Aesthetics, Inc. Multi-modality treatment systems, methods and apparatus for altering subcutaneous lipid-rich tissue
US9844460B2 (en) 2013-03-14 2017-12-19 Zeltiq Aesthetics, Inc. Treatment systems with fluid mixing systems and fluid-cooled applicators and methods of using the same
WO2014146022A2 (en) 2013-03-15 2014-09-18 Guided Therapy Systems Llc Ultrasound treatment device and methods of use
ES2941665T3 (es) 2013-07-03 2023-05-24 Histosonics Inc Secuencias de excitación de histotricia optimizadas para la formación de nubes de burbujas usando dispersión de choque
US11432900B2 (en) 2013-07-03 2022-09-06 Histosonics, Inc. Articulating arm limiter for cavitational ultrasound therapy system
US10779885B2 (en) 2013-07-24 2020-09-22 Miradry. Inc. Apparatus and methods for the treatment of tissue using microwave energy
WO2015027164A1 (en) 2013-08-22 2015-02-26 The Regents Of The University Of Michigan Histotripsy using very short ultrasound pulses
CN103537018A (zh) * 2013-11-01 2014-01-29 彭伟 超声波美容仪
US10575890B2 (en) 2014-01-31 2020-03-03 Zeltiq Aesthetics, Inc. Treatment systems and methods for affecting glands and other targeted structures
US10675176B1 (en) 2014-03-19 2020-06-09 Zeltiq Aesthetics, Inc. Treatment systems, devices, and methods for cooling targeted tissue
USD777338S1 (en) 2014-03-20 2017-01-24 Zeltiq Aesthetics, Inc. Cryotherapy applicator for cooling tissue
WO2015160708A1 (en) 2014-04-18 2015-10-22 Ulthera, Inc. Band transducer ultrasound therapy
US10952891B1 (en) 2014-05-13 2021-03-23 Zeltiq Aesthetics, Inc. Treatment systems with adjustable gap applicators and methods for cooling tissue
US10568759B2 (en) 2014-08-19 2020-02-25 Zeltiq Aesthetics, Inc. Treatment systems, small volume applicators, and methods for treating submental tissue
US10935174B2 (en) 2014-08-19 2021-03-02 Zeltiq Aesthetics, Inc. Stress relief couplings for cryotherapy apparatuses
ES2948135T3 (es) 2015-06-24 2023-08-31 Univ Michigan Regents Sistemas de terapia de histotripsia para el tratamiento del tejido cerebral
WO2017070112A1 (en) 2015-10-19 2017-04-27 Zeltiq Aesthetics, Inc. Vascular treatment systems, cooling devices, and methods for cooling vascular structures
CA3009414A1 (en) 2016-01-07 2017-07-13 Zeltiq Aesthetics, Inc. Temperature-dependent adhesion between applicator and skin during cooling of tissue
PL3405294T3 (pl) 2016-01-18 2023-05-08 Ulthera, Inc. Kompaktowe urządzenie ultradźwiękowe posiadające pierścieniowy zestaw ultradźwiękowy obwodowo połączony elektrycznie z elastyczną płytką drukowaną
US10765552B2 (en) 2016-02-18 2020-09-08 Zeltiq Aesthetics, Inc. Cooling cup applicators with contoured heads and liner assemblies
US10682297B2 (en) 2016-05-10 2020-06-16 Zeltiq Aesthetics, Inc. Liposomes, emulsions, and methods for cryotherapy
US10555831B2 (en) 2016-05-10 2020-02-11 Zeltiq Aesthetics, Inc. Hydrogel substances and methods of cryotherapy
US11382790B2 (en) 2016-05-10 2022-07-12 Zeltiq Aesthetics, Inc. Skin freezing systems for treating acne and skin conditions
IL293809B2 (en) 2016-08-16 2023-09-01 Ulthera Inc Systems and methods for cosmetic treatment of the skin using ultrasound
BR112019018277A2 (pt) 2017-03-01 2020-06-30 Endo Ventures Limited aparelho e método para avaliar e tratar celulite
MX2019011574A (es) 2017-03-28 2019-12-19 Endo Ventures Ltd Método mejorado para producir aplicaciones relacionadas con la colagenasa.
US11076879B2 (en) 2017-04-26 2021-08-03 Zeltiq Aesthetics, Inc. Shallow surface cryotherapy applicators and related technology
WO2019164836A1 (en) 2018-02-20 2019-08-29 Ulthera, Inc. Systems and methods for combined cosmetic treatment of cellulite with ultrasound
WO2020028472A1 (en) 2018-07-31 2020-02-06 Zeltiq Aesthetics, Inc. Methods, devices, and systems for improving skin characteristics
USD883767S1 (en) 2018-10-10 2020-05-12 A Hoyos Llc Handle
US11813484B2 (en) 2018-11-28 2023-11-14 Histosonics, Inc. Histotripsy systems and methods
US10902825B2 (en) * 2018-12-21 2021-01-26 Arris Enterprises Llc System and method for pre-filtering crawling overlay elements for display with reduced real-time processing demands
IT201900000679A1 (it) * 2019-01-16 2020-07-16 Fenix Group S R L Dispositivo integrato per il trattamento personalizzato non-invasivo di inestetismi cutanei e metodo multifase associato
US11813485B2 (en) 2020-01-28 2023-11-14 The Regents Of The University Of Michigan Systems and methods for histotripsy immunosensitization

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1362223A2 (de) * 2001-01-03 2003-11-19 Ultrashape Inc. Eingriffsfreie ultraschall körperkonturierung

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3113558A (en) * 1960-12-29 1963-12-10 Leonard L Marraffino Marking device
US3637437A (en) * 1970-06-03 1972-01-25 Catalytic Technology Corp Raney metal sheet material
US3735755A (en) * 1971-06-28 1973-05-29 Interscience Research Inst Noninvasive surgery method and apparatus
GB1487485A (en) * 1974-02-05 1977-09-28 Siemens Ag Method of forming a catalytic layer
US4049580A (en) * 1976-07-23 1977-09-20 The United States Of America As Represented By The Secretary Of The Interior Method for producing supported Raney nickel catalyst
US4043946A (en) * 1976-07-30 1977-08-23 The United States Of America As Represented By The Secretary Of The Interior Production of supported Raney nickel catalysts by reactive diffusion
US4116804A (en) * 1976-11-17 1978-09-26 E. I. Du Pont De Nemours And Company Catalytically active porous nickel electrodes
US4169025A (en) * 1976-11-17 1979-09-25 E. I. Du Pont De Nemours & Company Process for making catalytically active Raney nickel electrodes
US4110257A (en) * 1977-07-01 1978-08-29 The United States Of America As Represented By The United States Department Of Energy Raney nickel catalytic device
US4450056A (en) * 1981-11-23 1984-05-22 Olin Corporation Raney alloy coated cathode for chlor-alkali cells
JPS58181399A (ja) 1982-04-16 1983-10-24 Oki Electric Ind Co Ltd 多素子配列型ランジユバン振動子の製造方法
FR2543817B1 (fr) * 1983-04-06 1986-06-27 Rabelais Universite Francois Sonde endoscopique de visualisation et d'echographie ultrasonore a balayage
US5143073A (en) 1983-12-14 1992-09-01 Edap International, S.A. Wave apparatus system
US5431621A (en) 1984-11-26 1995-07-11 Edap International Process and device of an anatomic anomaly by means of elastic waves, with tracking of the target and automatic triggering of the shootings
US4827911A (en) * 1986-04-02 1989-05-09 Cooper Lasersonics, Inc. Method and apparatus for ultrasonic surgical fragmentation and removal of tissue
DE3704909A1 (de) * 1987-02-17 1988-08-25 Wolf Gmbh Richard Einrichtung zur raeumlichen ortung und zerstoerung von koerperinneren objekten mit ultraschall
US4727903A (en) * 1987-06-26 1988-03-01 Malcolm B. Sturgis Fluid shutoff valve
FR2619003B1 (fr) 1987-08-05 1997-06-27 Toshiba Kk Appareil ultrasonore de traitement therapeutique
US4853122A (en) * 1987-09-15 1989-08-01 Bend Research, Inc. P-xylylenediamide/diimide composite RO membranes
US4991579A (en) * 1987-11-10 1991-02-12 Allen George S Method and apparatus for providing related images over time of a portion of the anatomy using fiducial implants
US5143063A (en) * 1988-02-09 1992-09-01 Fellner Donald G Method of removing adipose tissue from the body
US4886491A (en) * 1988-02-29 1989-12-12 Tulio Parisi Liposuction procedure with ultrasonic probe
US5209221A (en) * 1988-03-01 1993-05-11 Richard Wolf Gmbh Ultrasonic treatment of pathological tissue
US4951653A (en) * 1988-03-02 1990-08-28 Laboratory Equipment, Corp. Ultrasound brain lesioning system
US4826799A (en) * 1988-04-14 1989-05-02 W. R. Grace & Co.-Conn. Shaped catalyst and process for making it
US4938216A (en) * 1988-06-21 1990-07-03 Massachusetts Institute Of Technology Mechanically scanned line-focus ultrasound hyperthermia system
FR2643252B1 (fr) * 1989-02-21 1991-06-07 Technomed Int Sa Appareil de destruction selective de cellules incluant les tissus mous et les os a l'interieur du corps d'un etre vivant par implosion de bulles de gaz
US5079952A (en) * 1989-03-25 1992-01-14 Poppan Printing Co. Ultrasonic transducer assembly and ultrasonic acoustic microscope
ATE144124T1 (de) * 1991-12-20 1996-11-15 Technomed Medical Systems Schallwellen aussendende,thermische effekte und kavitationseffekte erzeugende vorrichtung fur die ultraschalltherapie
WO1993016641A1 (en) * 1992-02-21 1993-09-02 Diasonics, Inc. Ultrasound intracavity system for imaging therapy planning and treatment of focal disease
DE4212809C2 (de) 1992-04-16 1996-08-14 Siemens Ag Therapieeinrichtung zur Behandlung eines Lebewesens mit fokussierten akustischen Wellen
DE4302538C1 (de) 1993-01-29 1994-04-07 Siemens Ag Therapiegerät zur Ortung und Behandlung einer im Körper eines Lebewesens befindlichen Zone mit akustischen Wellen
US5413550A (en) * 1993-07-21 1995-05-09 Pti, Inc. Ultrasound therapy system with automatic dose control
US5419761A (en) * 1993-08-03 1995-05-30 Misonix, Inc. Liposuction apparatus and associated method
EP0670183B1 (de) * 1993-11-11 1996-07-17 GESELLSCHAFT FÜR ANLAGEN- UND REAKTORSICHERHEIT ( GRS) mbH Verfahren zur Herstellung einer hochporösen Katalysatorschicht aus einer Palladium- oder Platinlegierung
JPH07184907A (ja) * 1993-12-28 1995-07-25 Toshiba Corp 超音波治療装置
US5507790A (en) * 1994-03-21 1996-04-16 Weiss; William V. Method of non-invasive reduction of human site-specific subcutaneous fat tissue deposits by accelerated lipolysis metabolism
NO308264B1 (no) * 1994-03-22 2000-08-21 Western Atlas Int Inc Brønnloggesonde med tilnærmet sylindrisk oppstilling av piezo- elektriske akustiske transdusere for elektronisk styring og fokusering av akustiske signaler
US5694936A (en) * 1994-09-17 1997-12-09 Kabushiki Kaisha Toshiba Ultrasonic apparatus for thermotherapy with variable frequency for suppressing cavitation
JPH0889893A (ja) 1994-09-28 1996-04-09 Tokin Corp ボルト締めランジュバン型振動子
DE19507478C1 (de) * 1995-03-03 1996-05-15 Siemens Ag Therapiegerät zur Behandlung mit fokussiertem Ultraschall
DE69634714T2 (de) * 1995-03-31 2006-01-19 Kabushiki Kaisha Toshiba, Kawasaki Therapeutisches Ultraschallgerät
DE19515748A1 (de) * 1995-04-28 1996-10-31 Siemens Ag Gerät zur Behandlung mit akustischen Wellen
US6241753B1 (en) * 1995-05-05 2001-06-05 Thermage, Inc. Method for scar collagen formation and contraction
GB2303552A (en) 1995-07-24 1997-02-26 Gar Investment Corp Ultrasound apparatus for non invasive cellulite reduction
US5618275A (en) * 1995-10-27 1997-04-08 Sonex International Corporation Ultrasonic method and apparatus for cosmetic and dermatological applications
US6206873B1 (en) * 1996-02-13 2001-03-27 El. En. S.P.A. Device and method for eliminating adipose layers by means of laser energy
US5827204A (en) * 1996-11-26 1998-10-27 Grandia; Willem Medical noninvasive operations using focused modulated high power ultrasound
DE69815260T2 (de) * 1997-01-24 2004-05-13 Koninklijke Philips Electronics N.V. Bildanzeigevorrichtung
JPH10277483A (ja) 1997-04-04 1998-10-20 Daishinku Co ボルト締めランジュバン型振動子
US5884631A (en) 1997-04-17 1999-03-23 Silberg; Barry Body contouring technique and apparatus
US5993979A (en) * 1997-04-29 1999-11-30 E. I. Du Pont De Nemours And Company Skeletal columnar coatings
TW370458B (en) * 1997-08-11 1999-09-21 Matsushita Electric Works Ltd Ultrasonic facial apparatus
US6113558A (en) 1997-09-29 2000-09-05 Angiosonics Inc. Pulsed mode lysis method
US6071239A (en) 1997-10-27 2000-06-06 Cribbs; Robert W. Method and apparatus for lipolytic therapy using ultrasound energy
JPH11187493A (ja) 1997-12-19 1999-07-09 Shokuhin Sangyo Denshi Riyou Gijutsu Kenkyu Kumiai 球状ランジュバン型振動子
EP1060728B9 (de) 1998-02-05 2010-02-24 Miwa Science Laboratory Inc. Bestrahlungsvorrichtung mit ultraschallwellen, sowie nicht-therapeutisches behandlungsverfahren
US6039048A (en) * 1998-04-08 2000-03-21 Silberg; Barry External ultrasound treatment of connective tissue
US6086821A (en) * 1999-03-29 2000-07-11 The United States Of America As Represented By The Secretary Of The Navy Ultrasonic force differentiation assay
US6684097B1 (en) * 1999-04-22 2004-01-27 University Of Miami Intraoperative monitoring of temperature-induced tissue changes with a high-resolution digital x-ray system during thermotherapy
US6478793B1 (en) * 1999-06-11 2002-11-12 Sherwood Services Ag Ablation treatment of bone metastases
US6387116B1 (en) * 1999-06-30 2002-05-14 Pharmasonics, Inc. Methods and kits for the inhibition of hyperplasia in vascular fistulas and grafts
US6573213B1 (en) * 1999-07-16 2003-06-03 Degussa Ag Metal catalysts
US6595934B1 (en) * 2000-01-19 2003-07-22 Medtronic Xomed, Inc. Methods of skin rejuvenation using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions
US6384516B1 (en) * 2000-01-21 2002-05-07 Atl Ultrasound, Inc. Hex packed two dimensional ultrasonic transducer arrays
US6479262B1 (en) * 2000-05-16 2002-11-12 Hercules, Incorporated Solid phase enzymatic assembly of polynucleotides
US20020156415A1 (en) * 2000-08-24 2002-10-24 Redding Bruce K. Ultrasonically enhanced substance delivery system and device
US6524250B1 (en) 2000-09-19 2003-02-25 Pearl Technology Holdings, Llc Fat layer thickness mapping system to guide liposuction surgery
US6575922B1 (en) * 2000-10-17 2003-06-10 Walnut Technologies Ultrasound signal and temperature monitoring during sono-thrombolysis therapy
US6645162B2 (en) * 2000-12-27 2003-11-11 Insightec - Txsonics Ltd. Systems and methods for ultrasound assisted lipolysis
US6607498B2 (en) * 2001-01-03 2003-08-19 Uitra Shape, Inc. Method and apparatus for non-invasive body contouring by lysing adipose tissue
US7347855B2 (en) * 2001-10-29 2008-03-25 Ultrashape Ltd. Non-invasive ultrasonic body contouring
JP4551090B2 (ja) * 2002-02-20 2010-09-22 メディシス テクノロジーズ コーポレイション 脂肪組織の超音波処理および画像化
US7331951B2 (en) * 2002-06-25 2008-02-19 Ultrashape Inc. Devices and methodologies useful in body aesthetics
US20040049134A1 (en) * 2002-07-02 2004-03-11 Tosaya Carol A. System and methods for treatment of alzheimer's and other deposition-related disorders of the brain
JP4422421B2 (ja) * 2003-03-17 2010-02-24 株式会社日立メディコ 超音波撮像装置
US20050283097A1 (en) * 2004-06-18 2005-12-22 Ultrastop Ltd. Devices and methodologies useful in non invasive termination of pregnancy
US20060241440A1 (en) * 2005-02-07 2006-10-26 Yoram Eshel Non-thermal acoustic tissue modification

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1362223A2 (de) * 2001-01-03 2003-11-19 Ultrashape Inc. Eingriffsfreie ultraschall körperkonturierung

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590370B2 (en) 2004-09-24 2023-02-28 Guided Therapy Systems, Llc Rejuvenating skin by heating tissue for cosmetic treatment of the face and body
US10238894B2 (en) 2004-10-06 2019-03-26 Guided Therapy Systems, L.L.C. Energy based fat reduction
US10245450B2 (en) 2004-10-06 2019-04-02 Guided Therapy Systems, Llc Ultrasound probe for fat and cellulite reduction
US10252086B2 (en) 2004-10-06 2019-04-09 Guided Therapy Systems, Llc Ultrasound probe for treatment of skin
US10265550B2 (en) 2004-10-06 2019-04-23 Guided Therapy Systems, L.L.C. Ultrasound probe for treating skin laxity
US11969609B2 (en) 2022-12-05 2024-04-30 Ulthera, Inc. Devices and methods for multi-focus ultrasound therapy

Also Published As

Publication number Publication date
AU2008202316A1 (en) 2008-06-19
WO2004000116A1 (en) 2003-12-31
BR0215785A (pt) 2006-06-06
US20080281236A1 (en) 2008-11-13
AU2002345319A1 (en) 2004-01-06
KR100923717B1 (ko) 2009-10-27
JP2005530548A (ja) 2005-10-13
CN1662177A (zh) 2005-08-31
KR20050019795A (ko) 2005-03-03
CA2490725A1 (en) 2003-12-31
US7331951B2 (en) 2008-02-19
AU2002345319B2 (en) 2008-03-06
EP1538980A4 (de) 2008-12-03
US20050261584A1 (en) 2005-11-24
EP1538980A1 (de) 2005-06-15
IL165909A0 (en) 2006-01-15
IL165909A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
EP1538980B1 (de) Vorrichtung für die körperästhetik
US7815570B2 (en) Non-invasive ultrasonic body contouring
US7347855B2 (en) Non-invasive ultrasonic body contouring
US20130310714A1 (en) Non-Thermal Acoustic Tissue Modification
US20100100014A1 (en) Non-Thermal Acoustic Tissue Modification
EP2600783A2 (de) Ultraschallbehandlungssysteme und -verfahren
US20040267120A1 (en) Method and instrumentation to sense thermal lesion formation by ultrasound imaging
KR20120117510A (ko) 초음파 치료장치 및 그 장치의 구동 방법
IL156439A (en) Non-invasive ultrasonic body contouring
KR20080028352A (ko) 비가열적 음향 조직 변형

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20081103

17Q First examination report despatched

Effective date: 20090414

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ULTRASHAPE LTD.

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 60248629

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61B0005055000

Ipc: A61N0007000000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61N 7/00 20060101AFI20160223BHEP

INTG Intention to grant announced

Effective date: 20160317

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

INTC Intention to grant announced (deleted)
GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

INTG Intention to grant announced

Effective date: 20161212

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 862556

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60248629

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170118

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 862556

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170118

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170118

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170419

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170118

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170518

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170118

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170118

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60248629

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170118

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170118

26N No opposition filed

Effective date: 20171019

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170118

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170630

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170625

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170625

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20170630

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170630

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20190612

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20190510

Year of fee payment: 18

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170118

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20190619

Year of fee payment: 18

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170118

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60248629

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20200625

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200625

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210101